Joachim Potgieter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joachim Potgieter has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Johnny Mahlangu
University of the Witwatersrand
3 shared publications - Jessica Opie
Department of Pathology, Division of Haematology, National Health Laboratory Service, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
2 shared publications - Tshiphiri Netshidzivhani
Department of Haematology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa; and, Department of Haematology, Tshwane Academic Division, National Health Laboratory Service, Pretoria
2 shared publications - Zivanai Cuthbert Chapanduka
Stellenbosch University
2 shared publications A Iorio
Department of Health Research, Impact and Evidence and Department of Medicine, McMaster University, Hamilton, Ontario, Canada
1 shared publicationA-L Cruickshank
Groote Schuur Hospital and Department of Haematology, Faculty of Health Sciences, University of Cape Town, South Africa
1 shared publication
Latest Publications
- Open Access
- 19 February 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (6) , e70180
Validation of the Primerdesign Quantitative Allele Specific Amplification Kit for the Detection of JAK2V617F Mutation
Introduction: Janus Kinase 2 (JAK2) is a tyrosine kinase involved in cellular signalling. A point mutation in codon 617 of JAK2 (JAK2V617F) causes a gain‐of‐function effect that stimulates proliferation of myeloid cells. The aim of this study was to evaluate the Primerdesign quantitative allele‐specific amplification (Quasa) kit for the detection of JAK2V617F. Methods: Specimens previously evaluated using real‐time PCR with melting curve analysis were analysed using the Quasa kit on the Bio‐Rad CFX 96 platform. Results of the two PCR tests were compared to evaluate the accuracy of the kit. For intra‐assay precision, samples were analysed in duplicate on the same run, and for inter‐assay variation, the same known samples were tested on three non‐consecutive days. The analytical sensitivity and quantitative analysis of the assay were determined using the World Health Organization (WHO) 1st International Reference Panel for Genomic JAK2V617F (United Kingdom Official Medicines Control Laboratory) and the United Kingdom National External Quality Assessment Service (UK NEQAS) results of their JAK2 p.val617phe (V617F) Mutation Status Programme. Results: Concordance of the qualitative test results between the test methods was 100%. Precision experiments confirmed repeatability and reproducibility. Analytical sensitivity was confirmed at 0.1%. Conclusion: The PrimerDesign Quasa kit for the detection of JAK2V617F is a sensitive and reliable assay that yields reproducible qualitative results. The kit is commercially available and has, in addition, the potential for quantitative analysis when samples are analysed in duplicate. This kit assay validation may be valuable to laboratories offering or interested in offering JAK2V617F mutational testing.
- 19 February 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (6) , e70180
Open AccessValidation of the Primerdesign Quantitative Allele Specific Amplification Kit for the Detection of JAK2V617F Mutation
Introduction: Janus Kinase 2 (JAK2) is a tyrosine kinase involved in cellular signalling. A point mutation in codon 617 of JAK2 (JAK2V617F) causes a gain‐of‐function effect that stimulates proliferation of myeloid cells. The aim of this study was to evaluate the Primerdesign quantitative allele‐specific amplification (Quasa) kit for the detection of JAK2V617F. Methods: Specimens previously evaluated using real‐time PCR with melting curve analysis were analysed using the Quasa kit on the Bio‐Rad CFX 96 platform. Results of the two PCR tests were compared to evaluate the accuracy of the kit. For intra‐assay precision, samples were analysed in duplicate on the same run, and for inter‐assay variation, the same known samples were tested on three non‐consecutive days. The analytical sensitivity and quantitative analysis of the assay were determined using the World Health Organization (WHO) 1st International Reference Panel for Genomic JAK2V617F (United Kingdom Official Medicines Control Laboratory) and the United Kingdom National External Quality Assessment Service (UK NEQAS) results of their JAK2 p.val617phe (V617F) Mutation Status Programme. Results: Concordance of the qualitative test results between the test methods was 100%. Precision experiments confirmed repeatability and reproducibility. Analytical sensitivity was confirmed at 0.1%. Conclusion: The PrimerDesign Quasa kit for the detection of JAK2V617F is a sensitive and reliable assay that yields reproducible qualitative results. The kit is commercially available and has, in addition, the potential for quantitative analysis when samples are analysed in duplicate. This kit assay validation may be valuable to laboratories offering or interested in offering JAK2V617F mutational testing.
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 4 (1)
The genetic profile of B-cell acute lymphoblastic leukaemia diagnosed in Pretoria, South Africa: A 10-year retrospective study
Background: B-cell acute lymphoblastic leukaemia (B-ALL) comprises genetically distinct subtypes with important prognostic implications. South African data suggest a different genetic landscape to other geographic regions, with a higher frequency of t(1;19). This study aimed to describe the genetic profile of B-ALL diagnosed at a South African tertiary haematology laboratory over a 10-year period. Methods: In this retrospective, descriptive study, all B-ALL cases (2014–2023) recorded in flow cytometry and cancer registries were identified. Demographic and laboratory data, including immunophenotypic and genetic findings, were extracted from the laboratory information system. Genetic work-up included karyotyping, a routine fluorescence in situ hybridisation panel: KMT2A rearrangement, t(1;19), t(12;21) and t(9;22), and real-time quantitative polymerase chain reaction where available. Results: A total of 173 patients were included (54.9% male; 75.7% < 19 years). Genetic testing was requested in 146 cases (84.4%), with definitive results in 115 (78.8%). Among informative cases, t(1;19) was most frequent (26.1%), followed by t(9;22) (12.2%), t(12;21) (10.4%), high hyperdiploidy (9.6%), KMT2A rearrangement (7.0%) and hypodiploidy (0.9%). The t(1;19) translocation predominated in paediatric patients, while t(9;22) was more common in adults. Both t(12;21) and KMT2A rearrangements were restricted to patients < 19 years. Conclusion: This cohort demonstrates a high frequency of t(1;19) and age-specific variation in B-ALL genetic subtypes, suggesting a distinct regional genetic profile. Expanded diagnostic testing and multicentre African studies are needed to refine risk stratification and guide context-appropriate care. Contribution: This study provides data on the distribution of selected genetic subtypes of B-ALL in a South African population, identifying differences in subtype frequency and age distribution that may inform regional diagnostic strategies and risk-directed care.
- 1 January 2026
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 4 (1)
Open AccessThe genetic profile of B-cell acute lymphoblastic leukaemia diagnosed in Pretoria, South Africa: A 10-year retrospective study
Background: B-cell acute lymphoblastic leukaemia (B-ALL) comprises genetically distinct subtypes with important prognostic implications. South African data suggest a different genetic landscape to other geographic regions, with a higher frequency of t(1;19). This study aimed to describe the genetic profile of B-ALL diagnosed at a South African tertiary haematology laboratory over a 10-year period. Methods: In this retrospective, descriptive study, all B-ALL cases (2014–2023) recorded in flow cytometry and cancer registries were identified. Demographic and laboratory data, including immunophenotypic and genetic findings, were extracted from the laboratory information system. Genetic work-up included karyotyping, a routine fluorescence in situ hybridisation panel: KMT2A rearrangement, t(1;19), t(12;21) and t(9;22), and real-time quantitative polymerase chain reaction where available. Results: A total of 173 patients were included (54.9% male; 75.7% < 19 years). Genetic testing was requested in 146 cases (84.4%), with definitive results in 115 (78.8%). Among informative cases, t(1;19) was most frequent (26.1%), followed by t(9;22) (12.2%), t(12;21) (10.4%), high hyperdiploidy (9.6%), KMT2A rearrangement (7.0%) and hypodiploidy (0.9%). The t(1;19) translocation predominated in paediatric patients, while t(9;22) was more common in adults. Both t(12;21) and KMT2A rearrangements were restricted to patients < 19 years. Conclusion: This cohort demonstrates a high frequency of t(1;19) and age-specific variation in B-ALL genetic subtypes, suggesting a distinct regional genetic profile. Expanded diagnostic testing and multicentre African studies are needed to refine risk stratification and guide context-appropriate care. Contribution: This study provides data on the distribution of selected genetic subtypes of B-ALL in a South African population, identifying differences in subtype frequency and age distribution that may inform regional diagnostic strategies and risk-directed care.
- Open Access
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 65-70
Occult hepatitis B virus infection in people with haemophilia in South Africa
Background: Occult hepatitis B virus (HBV) infection (OBI) is defined as the presence of HBV DNA in the absence of HBV surface antigen (HBsAg) serological markers. Despite the high prevalence of HBV infection in many communities, OBI prevalence among people with haemophilia (PWH) remains poorly characterised in South Africa. Aims: The aim of the study was to determine the prevalence of OBI and characterise viral complications of patients attending haemophilia clinics in three tertiary hospitals in Gauteng, namely, the Steve Biko Academic Hospital (SBAH), Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Dr George Mukhari Academic Hospital (DGMAH). Methods: This descriptive cross-sectional study was approved by the ethics committees of each participant centre. Haemophilia patients of any severity or inhibitor status with positive serological markers of HBV infection and immunity were excluded from the study. We measured Hepatitis B DNA of those with negative serological markers using a quantitative hepatitis B PCR assay. Results: Of the 76 patients screened, 66 male patients were included in the study. The median age was 29 years. Haemophilia A and haemophilia B comprised 89% and 11% of the cohort, respectively. The majority of patients were taking prophylactic factor replacement therapy (72%) as opposed to episodic therapy (28%). A total of 10 patients (15%) had inhibitors. Five patients (8%) were HIV seropositive. Ten patients (15%) had no documented evidence of being vaccinated against hepatitis B infection. Anti-hepatitis B core antibodies were positive in 5 patients (8%). All patients had a negative hepatitis B surface antigen result. All patients demonstrated negative hepatitis B PCR results. Conclusion: In this cohort of PWH from 3 centres, none showed evidence of occult HBV infection.
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 65-70
Open AccessOccult hepatitis B virus infection in people with haemophilia in South Africa
Background: Occult hepatitis B virus (HBV) infection (OBI) is defined as the presence of HBV DNA in the absence of HBV surface antigen (HBsAg) serological markers. Despite the high prevalence of HBV infection in many communities, OBI prevalence among people with haemophilia (PWH) remains poorly characterised in South Africa. Aims: The aim of the study was to determine the prevalence of OBI and characterise viral complications of patients attending haemophilia clinics in three tertiary hospitals in Gauteng, namely, the Steve Biko Academic Hospital (SBAH), Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Dr George Mukhari Academic Hospital (DGMAH). Methods: This descriptive cross-sectional study was approved by the ethics committees of each participant centre. Haemophilia patients of any severity or inhibitor status with positive serological markers of HBV infection and immunity were excluded from the study. We measured Hepatitis B DNA of those with negative serological markers using a quantitative hepatitis B PCR assay. Results: Of the 76 patients screened, 66 male patients were included in the study. The median age was 29 years. Haemophilia A and haemophilia B comprised 89% and 11% of the cohort, respectively. The majority of patients were taking prophylactic factor replacement therapy (72%) as opposed to episodic therapy (28%). A total of 10 patients (15%) had inhibitors. Five patients (8%) were HIV seropositive. Ten patients (15%) had no documented evidence of being vaccinated against hepatitis B infection. Anti-hepatitis B core antibodies were positive in 5 patients (8%). All patients had a negative hepatitis B surface antigen result. All patients demonstrated negative hepatitis B PCR results. Conclusion: In this cohort of PWH from 3 centres, none showed evidence of occult HBV infection.
- Open Access
- 14 November 2024
- Published by AOSIS in South African Journal of Oncology
- Vol. 8, 10
The genetic landscape of acute myeloid leukaemia in the South African public sector
Background: Acute myeloid leukaemia (AML) is a heterogeneous group of myeloid neoplasms for which two international classification systems exist: the 2022 World Health Organization (WHO) and international consensus classification of myeloid neoplasms (ICC), with an emphasis on molecular abnormalities.Aim: To determine the molecular-genetic profile of AML in the South African public sector.Setting: The Charlotte Maxeke Johannesburg Academic Hospital, Somatic Cell Genetics Unit, National Health Laboratory Service, South Africa.Methods: All newly diagnosed AML cases analysed with next generation sequencing (NGS) between January 2019 and December 2022 were retrospectively reviewed. Clinical and laboratory data were obtained from the laboratory information system.Results: In total, 194 AML cases were tested by NGS (162 classifiable), with a median age of 42 years for adults and 7 years for the paediatric cohort. There were 21 cases of AML with mutated TP53 (ICC), 5 of which were unclassifiable with the WHO classification system. In t(8;21) (q22;q22.1), KIT and FLT3-ITD mutations were present in 43% and 20% of cases respectively; FLT3-ITD in 50% of acute promyelocytic leukaemia (APL) and ~20% of AML with NPM1 were triple mutated (NPM1, DNMT3A, FLT3-ITD).Conclusion: This study revealed a high proportion of exon 17 KIT mutations in t(8;21), FLT3-ITD mutations in APL and triple mutated AML with mutated NPM1, all of which are likely to be driving the poor outcomes seen in these AML subgroups in our setting.Contribution: This is the first nationwide description of the molecular-genetic landscape of AML in the South African public sector.
- 14 November 2024
- Published by AOSIS in South African Journal of Oncology
- Vol. 8, 10
Open AccessThe genetic landscape of acute myeloid leukaemia in the South African public sector
Background: Acute myeloid leukaemia (AML) is a heterogeneous group of myeloid neoplasms for which two international classification systems exist: the 2022 World Health Organization (WHO) and international consensus classification of myeloid neoplasms (ICC), with an emphasis on molecular abnormalities.Aim: To determine the molecular-genetic profile of AML in the South African public sector.Setting: The Charlotte Maxeke Johannesburg Academic Hospital, Somatic Cell Genetics Unit, National Health Laboratory Service, South Africa.Methods: All newly diagnosed AML cases analysed with next generation sequencing (NGS) between January 2019 and December 2022 were retrospectively reviewed. Clinical and laboratory data were obtained from the laboratory information system.Results: In total, 194 AML cases were tested by NGS (162 classifiable), with a median age of 42 years for adults and 7 years for the paediatric cohort. There were 21 cases of AML with mutated TP53 (ICC), 5 of which were unclassifiable with the WHO classification system. In t(8;21) (q22;q22.1), KIT and FLT3-ITD mutations were present in 43% and 20% of cases respectively; FLT3-ITD in 50% of acute promyelocytic leukaemia (APL) and ~20% of AML with NPM1 were triple mutated (NPM1, DNMT3A, FLT3-ITD).Conclusion: This study revealed a high proportion of exon 17 KIT mutations in t(8;21), FLT3-ITD mutations in APL and triple mutated AML with mutated NPM1, all of which are likely to be driving the poor outcomes seen in these AML subgroups in our setting.Contribution: This is the first nationwide description of the molecular-genetic landscape of AML in the South African public sector.
- Open Access
- 12 August 2022
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 11 (1) , 5
Establishment of haemoglobin A2 reference intervals in Pretoria, South Africa: A retrospective secondary data analysis
Background: Haemoglobinopathies are one of the most common inherited diseases worldwide. Quantification of haemoglobin A2 is necessary for the diagnosis of the beta thalassaemia trait. In this context, it is important to have a reliable reference interval for haemoglobin A2 and a local reference range for South Africa has not been established.Objective: This study aimed to establish reference intervals for haemoglobin A2 using stored patient laboratory data.Methods: This descriptive study used retrospective data to evaluate haemoglobin A2 levels determined using high-performance liquid chromatography at the National Health Laboratory Service haematology laboratory in Pretoria, South Africa. All tests performed from 01 October 2012 to 31 December 2020 were screened for inclusion; of these, 144 patients’ data met the selection criteria. The reference interval was calculated using descriptive statistics (mean and standard deviation) with a 95% confidence interval.Results: Analysed data from enrolled patients showed a normal distribution. The mean age of the patients was 40 years (range: 3–84 years). The reference interval for haemoglobin A2 calculated from this data was 2.3% – 3.6%. The minimum haemoglobin A2 was 2.3% and the maximum was 3.9% with a mean of 2.95% and a standard deviation of 0.357%.Conclusion: A normal reference interval has been established for the population served by the laboratory that will assist with accurate diagnosis of the beta thalassaemia trait. This reference interval may also be useful to other laboratories that employ the same technology, especially smaller laboratories where obtaining a sufficiently large number of normal controls may be challenging.
- 12 August 2022
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 11 (1) , 5
Open AccessEstablishment of haemoglobin A2 reference intervals in Pretoria, South Africa: A retrospective secondary data analysis
Background: Haemoglobinopathies are one of the most common inherited diseases worldwide. Quantification of haemoglobin A2 is necessary for the diagnosis of the beta thalassaemia trait. In this context, it is important to have a reliable reference interval for haemoglobin A2 and a local reference range for South Africa has not been established.Objective: This study aimed to establish reference intervals for haemoglobin A2 using stored patient laboratory data.Methods: This descriptive study used retrospective data to evaluate haemoglobin A2 levels determined using high-performance liquid chromatography at the National Health Laboratory Service haematology laboratory in Pretoria, South Africa. All tests performed from 01 October 2012 to 31 December 2020 were screened for inclusion; of these, 144 patients’ data met the selection criteria. The reference interval was calculated using descriptive statistics (mean and standard deviation) with a 95% confidence interval.Results: Analysed data from enrolled patients showed a normal distribution. The mean age of the patients was 40 years (range: 3–84 years). The reference interval for haemoglobin A2 calculated from this data was 2.3% – 3.6%. The minimum haemoglobin A2 was 2.3% and the maximum was 3.9% with a mean of 2.95% and a standard deviation of 0.357%.Conclusion: A normal reference interval has been established for the population served by the laboratory that will assist with accurate diagnosis of the beta thalassaemia trait. This reference interval may also be useful to other laboratories that employ the same technology, especially smaller laboratories where obtaining a sufficiently large number of normal controls may be challenging.
- Open Access
- 1 January 2020
- Published by AOSIS in The Journal of Medical Laboratory Science and Technology of South Africa
- Vol. 2 (1) , 6-12
Guidelines for lupus anticoagulant testing in South Africa
- 1 January 2020
- Published by AOSIS in The Journal of Medical Laboratory Science and Technology of South Africa
- Vol. 2 (1) , 6-12
Open AccessGuidelines for lupus anticoagulant testing in South Africa
- Open Access
- 10 September 2019
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 109 (8b) , 40-S46
HIV and haematopoiesis
Human immunodeficiency virus (HIV) infection not only leads to a compromised immune system, but also disrupts normal haematopoiesis, resulting in the frequent manifestation of cytopenias (anaemia, thrombocytopenia and neutropenia). Although there is a definite association between the severity of cytopenia and HIV disease stage, this relationship is not always linear. For example, cytopenias such as thrombocytopenia may occur during early stages of infection. The aetiology of these haematological abnormalities is complex and multifactorial, including drug-induced impaired haematopoiesis, bone marrow suppression due to infiltration of infectious agents or malignant cells, HIV-induced impaired haematopoiesis, and several other factors. In this review, we describe the frequencies of anaemia, thrombocytopenia and neutropenia reported for HIV-infected, treatment-naïve cohorts studied in eastern and southern sub-Saharan African countries. We present a rational approach for the use of diagnostic tests during the workup of HIV-infected patients presenting with cytopenia, and discuss how HIV impacts on haematopoietic stem/progenitor cells (HSPCs) resulting in impaired haematopoiesis. Finally, we describe the direct and indirect effects of HIV on HSPCs which result in defective haematopoiesis leading to cytopenias.
- 10 September 2019
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 109 (8b) , 40-S46
Open AccessHIV and haematopoiesis
Human immunodeficiency virus (HIV) infection not only leads to a compromised immune system, but also disrupts normal haematopoiesis, resulting in the frequent manifestation of cytopenias (anaemia, thrombocytopenia and neutropenia). Although there is a definite association between the severity of cytopenia and HIV disease stage, this relationship is not always linear. For example, cytopenias such as thrombocytopenia may occur during early stages of infection. The aetiology of these haematological abnormalities is complex and multifactorial, including drug-induced impaired haematopoiesis, bone marrow suppression due to infiltration of infectious agents or malignant cells, HIV-induced impaired haematopoiesis, and several other factors. In this review, we describe the frequencies of anaemia, thrombocytopenia and neutropenia reported for HIV-infected, treatment-naïve cohorts studied in eastern and southern sub-Saharan African countries. We present a rational approach for the use of diagnostic tests during the workup of HIV-infected patients presenting with cytopenia, and discuss how HIV impacts on haematopoietic stem/progenitor cells (HSPCs) resulting in impaired haematopoiesis. Finally, we describe the direct and indirect effects of HIV on HSPCs which result in defective haematopoiesis leading to cytopenias.
- Open Access
- 28 August 2019
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 109 (9) , 639-644
Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process
Background. Optimal care of patients with inherited bleeding disorders requires that bleeding episodes are treated early, or still better prevented, through extension of patient care beyond hospital-based treatment to home-based therapy. In South Africa (SA), adoption of home therapy is variable, in part owing to lack of consensus among healthcare providers on what constitutes home therapy, which patients should be candidates for it, how it should be monitored, and what the barriers to home therapy are. Objectives. To conduct a modified Delphi process in order to establish consensus on home therapy among haemophilia healthcare providers in SA. Methods. Treaters experienced in haemophilia care were invited to participate in a consensus-seeking process conducted in three rounds. In round 1, provisional statements around home therapy were formulated as questions and collated in a structured list. In rounds 2 and 3, evolving versions of the questionnaire were administered to participants. Consensus was defined as ≥70% agreement among the participants. Results. The panel composition included an equal number of physicians and non-physicians. The participation rate was 100% through all three consensus rounds. The group reached consensus for 92% of the statements. Consensus of 100% was reached on starting home therapy in paediatric patients, requiring all patients on home therapy to sign informed consent and indemnity, and providing round-the-clock support for patients on home therapy. Conclusions. The home therapy consensus statements in this report have the potential to translate to policy on home therapy and to guide the initiation, practice and evaluation of home therapy programmes in SA.
- 28 August 2019
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 109 (9) , 639-644
Open AccessHome therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process
Background. Optimal care of patients with inherited bleeding disorders requires that bleeding episodes are treated early, or still better prevented, through extension of patient care beyond hospital-based treatment to home-based therapy. In South Africa (SA), adoption of home therapy is variable, in part owing to lack of consensus among healthcare providers on what constitutes home therapy, which patients should be candidates for it, how it should be monitored, and what the barriers to home therapy are. Objectives. To conduct a modified Delphi process in order to establish consensus on home therapy among haemophilia healthcare providers in SA. Methods. Treaters experienced in haemophilia care were invited to participate in a consensus-seeking process conducted in three rounds. In round 1, provisional statements around home therapy were formulated as questions and collated in a structured list. In rounds 2 and 3, evolving versions of the questionnaire were administered to participants. Consensus was defined as ≥70% agreement among the participants. Results. The panel composition included an equal number of physicians and non-physicians. The participation rate was 100% through all three consensus rounds. The group reached consensus for 92% of the statements. Consensus of 100% was reached on starting home therapy in paediatric patients, requiring all patients on home therapy to sign informed consent and indemnity, and providing round-the-clock support for patients on home therapy. Conclusions. The home therapy consensus statements in this report have the potential to translate to policy on home therapy and to guide the initiation, practice and evaluation of home therapy programmes in SA.
- Open Access
- 31 January 2018
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 7 (1) , 4 pages
Detection of the Janus kinase 2 V617F mutation using a locked nucleic-acid, real-time polymerase chain reaction assay
The purpose of this study was to develop a real time polymerase chain reaction (PCR) assay for the detection of the JAK2 V617F mutation that could be used in diagnostic laboratories. Sanger sequencing and a newly developed locked nucleic-acid, real-time PCR assay were used to detect the JAK2 V617F mutation. There was 100% agreement between the sequencing and PCR analysis. Both assays were able to detect the mutation in all 24 of the 60 test specimens harbouring the mutation.
- 31 January 2018
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 7 (1) , 4 pages
Open AccessDetection of the Janus kinase 2 V617F mutation using a locked nucleic-acid, real-time polymerase chain reaction assay
The purpose of this study was to develop a real time polymerase chain reaction (PCR) assay for the detection of the JAK2 V617F mutation that could be used in diagnostic laboratories. Sanger sequencing and a newly developed locked nucleic-acid, real-time PCR assay were used to detect the JAK2 V617F mutation. There was 100% agreement between the sequencing and PCR analysis. Both assays were able to detect the mutation in all 24 of the 60 test specimens harbouring the mutation.
- Open Access
- 24 August 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (8) , e0161891
Human Immunodeficiency Virus (HIV)-Infected Patients Accept Finger Stick Blood Collection for Point-Of-Care CD4 Testing
HIV-infected patients require antiretroviral treatment for life. To improve access to care, CD4 enumeration and viral load tests have been redesigned to be used as point-of-care techniques using finger-stick blood. Accurate CD4 counting in capillary blood requires a free flowing blood drop that is achieved by blade incision. The aim of this study was to assess the attitude of the patients toward blade-based finger-stick blood donation. Four hundred and ninety-nine patients were included (299 patients from South Africa and 200 from Belgium). They completed a questionnaire to express their preference for finger stick or venipuncture, after undergoing both. The South African patient cohort was divided in two groups, receiving either single or multiple finger stick for CD4 and other HIV-related tests. The Belgian patients received a single finger stick for CD4 testing, and were asked to respond directly and again after two days. The majority of the patients preferred the finger stick to the venipuncture. The perceived pain using the blade was superior to a small needle, but similar to a large needle. They preferred up to three finger sticks over one venipuncture. Up to 30% of the patients changed their mind over two days. The main reason for choosing a finger stick was continued bleeding after venipuncture. The most cited objection to finger stick was pain/soreness. Patient perceptions support the implementation of donating capillary blood with blade-based finger stick during CD4 point-of-care testing.
- 24 August 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (8) , e0161891
Open AccessHuman Immunodeficiency Virus (HIV)-Infected Patients Accept Finger Stick Blood Collection for Point-Of-Care CD4 Testing
HIV-infected patients require antiretroviral treatment for life. To improve access to care, CD4 enumeration and viral load tests have been redesigned to be used as point-of-care techniques using finger-stick blood. Accurate CD4 counting in capillary blood requires a free flowing blood drop that is achieved by blade incision. The aim of this study was to assess the attitude of the patients toward blade-based finger-stick blood donation. Four hundred and ninety-nine patients were included (299 patients from South Africa and 200 from Belgium). They completed a questionnaire to express their preference for finger stick or venipuncture, after undergoing both. The South African patient cohort was divided in two groups, receiving either single or multiple finger stick for CD4 and other HIV-related tests. The Belgian patients received a single finger stick for CD4 testing, and were asked to respond directly and again after two days. The majority of the patients preferred the finger stick to the venipuncture. The perceived pain using the blade was superior to a small needle, but similar to a large needle. They preferred up to three finger sticks over one venipuncture. Up to 30% of the patients changed their mind over two days. The main reason for choosing a finger stick was continued bleeding after venipuncture. The most cited objection to finger stick was pain/soreness. Patient perceptions support the implementation of donating capillary blood with blade-based finger stick during CD4 point-of-care testing.